Does omega-3 supplementation improve the inflammatory profile of patients with heart failure? a systematic review and meta-analysis

PROKOPIDIS, Konstantinos, THERDYOTHIN, Atiporn, GIANNOS, Panagiotis, MORWANI-MANGNANI, Jordi, FERENTINOS, Panagiotis, MITROPOULOS, Alexandros and ISANEJAD, Masoud (2023). Does omega-3 supplementation improve the inflammatory profile of patients with heart failure? a systematic review and meta-analysis. Heart Failure Reviews, 28 (6), 1417-1425.

[img]
Preview
PDF
Mitropoulos-DoesOmega-3(VoR).pdf - Published Version
Creative Commons Attribution.

Download (857kB) | Preview
Official URL: http://dx.doi.org/10.1007/s10741-023-10327-0
Open Access URL: https://link.springer.com/content/pdf/10.1007/s107... (Published version)
Link to published version:: https://doi.org/10.1007/s10741-023-10327-0

Abstract

Omega-3 fatty acids are potential anti-inflammatory agents that may exert beneficial outcomes in diseases characterised by increased inflammatory profile. The purpose of this study was to comprehensively evaluate the existing research on the effectiveness of n-3 fatty acid supplementation in lowering levels of circulating inflammatory cytokines in patients with heart failure (HF). From the beginning until October 2022, randomised controlled trials (RCTs) were the subject of PubMed, Scopus, Web of Science, and Cochrane Library literature search. Omega-3 fatty acid supplementation vs. placebo were compared in eligible RCTs to see how they affected patients with HF in terms of inflammation, primarily of tumour necrosis factor-alpha (TNF-a), interleukin-6 (IL-6), and c-reactive protein (CRP). A meta-analysis employing the random effects inverse-variance model and standardised mean differences was performed to assess group differences. Ten studies were included in this systematic review and meta-analysis. Our main analysis (k=5) revealed a beneficial response of n-3 fatty acid supplementation on serum TNF-a (SMD:−1.13, 95% CI:−1.75–−0.50, I 2=81%, P=0.0004) and IL-6 levels (k=4; SMD:−1.27, 95% CI:−1.88–−0.66, I 2=81%, P<0.0001) compared to placebo; however, no changes were observed in relation to CRP (k=6; SMD:−0.14, 95% CI:−0.35–0.07, I 2=0%, P=0.20). Omega-3 fatty acid supplementation may be a useful strategy for reducing inflammation in patients with HF, but given the paucity of current studies, future studies may increase the reliability of these findings

Item Type: Article
Uncontrolled Keywords: 1102 Cardiorespiratory Medicine and Haematology; Cardiovascular System & Hematology; 3201 Cardiovascular medicine and haematology
Identification Number: https://doi.org/10.1007/s10741-023-10327-0
Page Range: 1417-1425
SWORD Depositor: Symplectic Elements
Depositing User: Symplectic Elements
Date Deposited: 02 Oct 2023 15:38
Last Modified: 17 Oct 2023 09:15
URI: https://shura.shu.ac.uk/id/eprint/32498

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics